KALRN: A Potential Drug Target and Biomarker (G8997)

Target Name: KALRN

NCBI ID: G8997

KALRN

KALRN: A Potential Drug Target and Biomarker

KALRN (Kinesin-Aldinal Glycoprotein RNA-N-terminal domain) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression and cell signaling. It is a protein kinase with DNA-binding and protein-binding domains, which gives it the ability to modulate the activity of various cellular proteins. The KALRN gene has five exons, and its protein product has a calculated molecular weight of 17.9 kDa.

KALRN is highly expressed in various tissues and organs, including brain, heart, liver, and muscle. It is also expressed in various cell types, including epithelial and endothelial cells, neural stem cells, and cancer cells. KALRN has been shown to be involved in various cellular processes, including cell signaling, cell cycle regulation, and tissue repair.

KALRN has been shown to play a critical role in the regulation of cell proliferation and cell cycle progression. It has been shown to inhibit the G1-S transition and promote the G0-G1 transition, which are critical steps in the cell cycle. also been shown to play a role in the regulation of cell differentiation and tissue regeneration.

In addition to its role in cell cycle regulation, KALRN has also been shown to play a critical role in the regulation of protein translation. It has been shown to interact with various protein translation factors, including porcupine album factor 1 (HIF1伪) and 4.1B protein. Through these interactions, KALRN can regulate protein expression and translation efficiency, thereby exerting important effects on cell function.

KALRN's protein products also have a variety of biological activities. For example, it can bind directly to DNA within cells, thereby regulating gene expression. It can also bind to proteins, thereby regulating their structure and function. In addition, KALRN can protect cells from oxidative stress damage by inhibiting apoptosis.

KALRN is also being studied as a drug target. Scientists have discovered that KALRN has potential applications in treating a variety of diseases. For example, studies have shown that inhibiting KALRN activity can inhibit the growth and spread of tumor cells. KALRN activity can also be inhibited to treat neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

In addition, KALRN can also be detected as a biomarker. Because KALRN is expressed in various diseases, it can serve as an important diagnostic biomarker for tumors and neurodegenerative diseases.

KALRN is a molecule with broad biological activities that can be studied as a drug target or biomarker. Future research will continue to further investigate KALRN's role in cell cycle regulation and protein translation, as well as its potential application value in the treatment of various diseases.

Protein Name: Kalirin RhoGEF Kinase

Functions: Promotes the exchange of GDP by GTP. Activates specific Rho GTPase family members, thereby inducing various signaling mechanisms that regulate neuronal shape, growth, and plasticity, through their effects on the actin cytoskeleton. Induces lamellipodia independent of its GEF activity

The "KALRN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KALRN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets